Important pregnancy insomnia Information


Subscribe


Tiny electric shock that will stop you grinding your teeth (Daily Mail)

Danish scientists have devised a novel way of treating teeth-grinding using an iPod-sized device that delivers an electric shock to the temples.

Presentation of results from open-label extension study of Xenazine announced (News-Medical-Net)

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p

Health briefs: Bollywood dance (The Beacon News)

Rush-Copley Healthplex invites the community to attend a kick-off event for its new Bollywood fitness class from 6 to 8 p.m. Friday. The Bollywood fitness class helps students get fit while learning a new style of dance. Most dances are relatively quick and include many arm and leg movements. No dance experience is necessary; wear comfortable shoes and clothes. Refreshments, body fat analysis ...

Data from Two Phase III Studies of Merck's Investigational Asthma Drug Presented at American Academy of Allergy ... (Business Wire via Yahoo! Finance)

NEW ORLEANS----Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology annual meeting.

Forest Laboratories Receives Decision From FDA For Supplemental New Drug Application For Bystolic(R) (Medical News Today)

Forest Laboratories, Inc. (NYSE: FRX) announced that the U.S. Food and Drug Administration (FDA) did not approve the additional indication for Bystolic(R) (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company's Supplemental New Drug Application (sNDA). Bystolic is currently approved in the US for the treatment of hypertension...

Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic® (Business Wire via Yahoo! Finance)

NEW YORK----Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® tablets as a treatment for stable chronic heart failure as requested in the company’s Supplemental New Drug Application .

Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppression In Phase II Study (Medical News Today)

Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to thatofAtripla(R) (efavirenz 600 mg/ emtricitabine 200 mg ...

Mark Hyman, MD: Mercury: How To Get This Lethal Poison Out Of Your Body (The Huffington Post)

There's no doubt about it, mercury is the most alarming, disease-causing source of environmental toxicity that I see daily in my practice.

Press Release (PharmiWeb)

Gilead Sciences Inc. Posted on:17 Feb 10 Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® ...

Gilead's Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study (Business Wire via Yahoo! Finance)

FOSTER CITY, Calif.----Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 and Truvada® for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® .